IRD
Opus Genetics, Inc.
4.40$
-4.4%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -25.2% | 269.0% | -334.1% | -655.8% | -132.7% | -172.9% | -205.8% | -356.3% | -200.0% | -254.4% | -590.0% | -1,582.8% | -412.6% | |
| 0.0% | 0.2% | 0.0% | 0.0% | 0.0% | 0.2% | 0.3% | 0.5% | 0.4% | 0.3% | 0.6% | 1.9% | 0.5% | |
| 4.8% | 42.0% | 57.6% | 72.5% | 20.1% | 18.5% | 20.9% | 31.1% | 26.5% | 20.0% | 67.9% | 186.4% | 45.3% | |
| -87.3% | 511.6% | 23.1% | -29.9% | 41.8% | 32.8% | -6.7% | -97.4% | 28.4% | 1.9% | -4.7% | 131.8% | 18.7% | |
| 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| – | – | – | – | – | 28.1% | – | – | – | – | – | – | – | |
| 0.0% | – | -2.5% | 0.0% | 0.0% | -0.9% | -0.8% | 15.4% | 169.4% | -3.0% | -1.5% | 4.4% | 51.8% | |
| 45.0% | 213.1% | 138.9% | 138.5% | 9.1% | -1.9% | 468.3% | 31.4% | 147.5% | 623.8% | 1,279.3% | 5,417.6% | 985.7% | |
| 19.9% | 482.0% | -195.2% | -517.3% | -123.5% | -146.7% | 262.5% | -324.9% | -52.4% | 369.4% | 689.3% | 3,834.8% | 573.1% | |
| -25.2% | 269.0% | -334.1% | -655.8% | -132.7% | -172.9% | -205.8% | -356.3% | -200.0% | -254.4% | -590.0% | -1,582.8% | -412.6% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.